Premier Medical Group PC — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$200,014	23
2024	Research	$366,615	13
2023	Research	$11,343	5
2022	Research	$159,366	32
2021	Research	$320,290	47
2020	Research	$8,645	7
2019	Research	$801	1

Breakdown

Who paid Research payments · program years 2019–2025

Madrigal Pharmaceuticals $566,629 36 payments
Pfizer Inc. $486,077 80 payments
GlaxoSmithKline, LLC. $13,567 11 payments
Eli Lilly and Company $801 1 payment

Studies the money was for Research payments · program years 2019–2025

A Phase 3 Multinational Doubleblind Randomized Placebocontrolled Study of Mgl3196 Resmetirom in Patients With Nonalcoholic Steatohepatitis Nash and Fibrosis to Resolve Nash and Reduce Progression to Cirrhosis Andor Hepatic Decompensation $510,752 20 payments
A Phase 3 Randomized Doubleblind Trial to Evaluate the Safety and Immunogenicity of A 20Valent Pneumococcal Conjugate Vaccine in Healthy Infants $258,776 36 payments
A Phase 3 Randomized Doubleblinded Placebocontrolled Trial to Evaluate the Efficacy and Safety of A Respiratory Syncytial Virus RSV Prefusion F Subunit Vaccine in Infants Born to Women Vaccinated During Pregnancy $161,963 31 payments
An Interventional Efficacy and Safety Phase 23 Doubleblind 2Arm Study to Investigate Orally Administered Pf07321332ritonavir Compared With Placebo in Nonhospitalized Symptomatic Adult Participants With Covid19 Who Are at Increased Risk of Progressing to Severe Illness $42,688 7 payments
A 52-Week, Phase 3, Open-Label Extension Study, With a Double-blind Lead-in, to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) $32,857 8 payments
A 52Week Phase 3 Openlabel Extension Study With A Doubleblind Leadin to Evaluate Safety and Biomarkers of Resmetirom Mgl3196 in Patients With Nonalcoholic Fatty Liver Disease Nafld Maestronafldopenlabelextension Maestronafldole $23,020 8 payments
An Interventional Efficacy and Safety Phase 23 Doubleblind 2 Arm Study to Investigate Orally Administered PF 07321332Ritonavir Compared With Placebo in Nonhospitalized Symptomatic Adult Participants With Covid19 Who Are at Low Risk of Progressing to Severe Illness $12,000 3 payments
A Phase 23 Randomized Doubleblind Doubledummy Placebo Controlled Study to Evaluate the Safety and Efficacy of 2 Regimens of Orally Administered PF 07321332Ritonavir in Preventing Symptomatic Sarscov2 Infection in Adult Household Contacts of An Individual With Symptomatic Covid19 $10,650 3 payments
Phase Iiib, Observer-Blind, Randomized, Placebo-Controlled, Multi-Cent $8,645 7 payments
Study name not reported $4,921 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.